Trial Profile
Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 May 2022
Price :
$35
*
At a glance
- Drugs Zalifrelimab (Primary)
- Indications Carcinoma; Liver cancer; Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Agenus
- 28 Apr 2022 Status changed from active, no longer recruiting to completed.
- 28 Dec 2021 Planned End Date changed from 15 Dec 2021 to 19 Dec 2023.
- 28 Dec 2021 Planned primary completion date changed from 31 Oct 2021 to 31 Mar 2022.